Please provide your email address to receive an email when new articles are posted on . The FDA has approved the subcutaneous formulation of Actemra for the treatment of polyarticular juvenile ...
The efficacy of Actemra SC among pediatric patients (ages 2–17) was extrapolated from established data of Actemra IV in PJIA patients and of Actemra SC in patients with rheumatoid arthritis. For SC ...
The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist. 1. Why am I using Actemra? Actemra contains the active ingredient ...
March 25, 2013 (Tokyo) - Chugai Pharmaceutical Co., Ltd. [Head Office: Chuo-ku Tokyo; Chairman & CEO: Osamu Nagayama (hereafter, "Chugai")] announced today that the subcutaneous injection formulation ...
The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist. 1. Why am I using Actemra? Actemra contains the active ingredient ...
GenentechMedia:Joe St. Martin, 650-467-6800orInvestor:Thomas Kudsk Larsen, 650-467-2016Karl Mahler, 011 41 61 687 85 03 Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback